Business Wire - December 19, 2008
PARIS--Regulatory News:
BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced that Dominique Costantini MD (President of the company's Executive Board) has won the Engineer of the Year Award in entrepreneurship category.
This award was attributed yesterday, Thursday December 18th, by an independent jury selected by two of France's leading trade magazines ("L'Usine Nouvelle" and "Industrie et Technologies"), in association with the French National Council of Engineers and Scientists (Conseil National des Ing nieurs et Scientifiques de France).
"I consider that this award marks the company's commitment and our staff's considerable energy and scientific & technical skills", commented Dominique Costantini. "We have chosen to innovate; in less than ten years, we have succeeded in building a novel type of integrated pharmaceutical company - one that is capable of developing a drug all the way through to market launch and creating an extensive portfolio of products that satisfy unmet patient needs", she concluded.
For more information, visit: lesingenieursdelannee.com and usinenouvelle.com
About BioAlliance Pharma
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address drug resistance issues. BioAlliance Pharma has launched its first portfolio product (Loramyc(R)) in France and, more recently, in the UK, Germany and Denmark, and has already received European Marketing Authorizations in Belgium and Luxemburg. The product has also completed a pivotal Phase III clinical trial in the United States in oropharyngeal candidiasis. The company is also performing a Phase III trial in labial herpes with acyclovir Lauriad(R) (which is based on the same Lauriad(R) muco-adhesive technology as Loramyc(R), enabling targeted release at the disease site). BioAlliance Pharma also has a second technology (the Transdrug(R) nanoparticle technology, designed specifically for intracellular targeting) and, furthermore, is developing a new therapeutic entities program in oncology and infectious disease. BioAlliance Pharma has established several strategic alliances for commercializing Loramyc(R), with agreements in 2007 for Europe (with the SpeBio joint venture) and the United States (with Par Pharmaceutical) and in 2008 for Asia (Korea, Malaysia, Singapore and Taiwan with Handok Pharmaceuticals and then China with Novamed). In May and August 2008, the company expanded its product portfolio by acquiring the Europe commercial rights to, respectively, ondansetron Oral Spray (OS) from NovaDel Pharma Inc. (Amex: NVD) and ondansetron RapidFilmTM from APR/Labtec. For more information, visit BioAlliance Pharma's website at www.bioalliancepharma.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 11 2008 under the number R. 08-021, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma S.A.'s website (http://www.bioalliancepharma.com).
Contacts
BioAlliance Pharma SA | Dominique Costantini, President and CEO | Tel.: +33 1 45 58 76 01 | dominique.costantini@bioalliancepharma.com
or
Nicolas Fellmann, CFO | Tel.: +33 1 45 58 71 00 | nicolas.fellmann@bioalliancepharma.com
or
ALIZE RP | Caroline Carmagnol | Tel.: +33 6 64 18 99 59 | caroline@alizerp.com
081219
BW081242
Copyright © 2008 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .